P values for univariate analysis of risk factors for transformation to secondary aggressive NHL, HL-FFTF, and TTP
| Clinical feature . | TTT to secondary NHL . | HL-FFTF (relapse NLPHL) . | TTP (relapse all lymphoma) . | OS . |
|---|---|---|---|---|
| Male gender | .149 | .040 | .113 | .504 |
| Age ≥45 years | .703 | .466 | .469 | .865 |
| B symptoms | .412 | .688 | .239 | .043 |
| PS ≥2 | .289 | .0007 | .058 | .025 |
| Splenic disease | .019 | .760 | .001 | .521 |
| Mass ≥5 cm | .011 | .194 | .480 | .645 |
| Elevated LDH | .198 | .306 | .904 | .493 |
| ABVD-like | .755 | .147 | .744 | .728 |
| Clinical feature . | TTT to secondary NHL . | HL-FFTF (relapse NLPHL) . | TTP (relapse all lymphoma) . | OS . |
|---|---|---|---|---|
| Male gender | .149 | .040 | .113 | .504 |
| Age ≥45 years | .703 | .466 | .469 | .865 |
| B symptoms | .412 | .688 | .239 | .043 |
| PS ≥2 | .289 | .0007 | .058 | .025 |
| Splenic disease | .019 | .760 | .001 | .521 |
| Mass ≥5 cm | .011 | .194 | .480 | .645 |
| Elevated LDH | .198 | .306 | .904 | .493 |
| ABVD-like | .755 | .147 | .744 | .728 |